Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • Delhi HC asks NPPA to...

Delhi HC asks NPPA to reconsider show cause issued to AstraZeneca over cancer drug Tagrisso

Medical Dialogues TeamWritten by Medical Dialogues Team Published On 2021-05-16T11:00:00+05:30  |  Updated On 16 May 2021 11:00 AM IST
Delhi HC asks NPPA to reconsider show cause issued to AstraZeneca over cancer drug Tagrisso
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has been directed by the Delhi High Court to reconsider and issue a fresh order to AstraZeneca Pharma India Limited over cancer drug Osimertinib (Tagrisso 80mg), adding that the Authority should not file any demand against the drugmaker until it issues a new order.

The Medical Dialogues team had reported earlier that the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Ministry of Health and Family Welfare, had granted AstraZeneca Pharma India Limited import and marketing approval for Osimertinib Film-coated Tablets 40mg/80mg (Osimertinib Mesylate) for lung cancer.

Also Read: CDSCO Grants Approval To AstraZeneca India For Breakthrough Therapy Of Lung Cancer

Osimertinib Film-coated Tablet is marketed under brand name Tagrisso 80mg. Osimertinib is used to treat locally advanced or metastatic non-small-cell lung cancer (NSCLC) when cancer has the specific T790M mutation in the gene coding for epidermal growth factor receptor.

The court order came following a petition submitted by AstraZeneca seeking to

(a) Pass an appropriate writ, order or declaration quashing the Gazette Notification dated February 27, 2019 issued by NPPA

(b) Pass an appropriate writ, order or declaration quashing the Show-Cause Notice dated October 14, 2020 issued by NPPA;

(c) Pass an appropriate writ, order or declaration quashing the Order dated January 13, 2021 passed by NPPA; and

(d) Pass any other or further order (s) which the Court deems fit in the interest of justice.

The learned Senior Counsel appearing for AstraZeneca submitted that NPPA, through an order dated 13th January 2021, directed the pharma firm to furnish CA certified data for selling Tagrisso 80mg tablet.

In addition to this, it was ensured that on 4th February 2021, AstraZeneca supplied the necessary details to NPPA in response to the order dated 13.01.2021.

The NPPA order dated 13.01.2021 read,

"6. Based on the abovementioned facts, the company has overcharged in the sale of Tagrisso 80mg tablet. The company has not submitted details of quantity sold since 08th March 2019 duly certified by Chartered Accountant as sought vide Show Cause Notice dated 14th October 2020. Therefore, the company is once again directed to furnish CA certified data for the sale of the formulation in reference in the Annexure attached herewith within 15 days of receipt of this order, failing which demand notice will be issued based on market data available with NPPA"

Challenging the show cause notice issued by NPPA, the Counsel for AstraZeneca further submitted that Osimertinib (Tagrisso 80mg tablet) is a patented product qualifying for exemption for five years from the date of commencement of its commercial marketing in India.

Therefore, Para 32 (i) of DPCO, 2013 stipulates that the provisions of the above-said order shall not apply to a manufacturer producing a new drug patented under the Indian Patent Act, 1970 for a period of five years from the date of commencement of its commercial marketing by the manufacturer in the country.

"The AstraZeneca pharma India Pvt. limited has a product patent covering the molecule OSIMERTINIB (TAGRISSO) and the same is valid for twenty years i.e. up to 24.07.2032. The Show Cause Notice dated 14.10.2020 and the impugned order dated 13.01.2021 is thus illegal and deserve to be quashed." added the Counsel for AstraZeneca.

In addition, apart from the various grounds urged to challenge the show cause notice and the impugned order, the Counsel also highlighted that the NPPA has no power, jurisdiction and authority to issue the aforesaid Show Cause Notice and raise a demand on the drugmaker.

After hearing the submissions made by AstraZeneca, the Delhi High Court noted,

" We have heard learned senior counsel for AstraZeneca and learned counsels for NPPA. We have perused the order dated 13.01.2021 and it is clear that NPPA has directed the pharma firm to furnish CA certified data before issuing a Demand Notice."

In view of the above observation, the Delhi High Court pronounced its order as quoted;

"Since the matter still rests at a stage where requisite information and data has been sought by NPPA and the decision is yet to be taken, we hereby direct NPPA to pass a fresh order taking into account the information given in the communication dated 4th February, 2021 by the petitioner and also the various contentions raised in the present writ petition including the reply(s) filed by the petitioner. The Authority will also consider the issue of jurisdiction raised herein and needless to state that the decision so taken on all counts shall be in accordance with law and after giving adequate opportunity of being heard to the petitioner."

It noted;

"Till the decision is taken by NPPA, it shall not raise any demand against the petitioner with regard to the issues in question. In case AstraZeneca is still aggrieved by the decision rendered by NPPA, it shall have the liberty to challenge the same in accordance with the law in the appropriate Forum."

In light of the above, the writ petition is disposed of along with the pending application.

To access the official order, click on the link below:-

https://indiankanoon.org/doc/43105145/

nppaosimertinibtagrissoDelhi High Courtastrazeneca newsastrazenecacancercancer drug
Medical Dialogues Team
Medical Dialogues Team
    Show Full Article
    Next Story

    Editorial

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    Aspirin in Primary Prevention- When to Consider?

    Aspirin in Primary Prevention- When to Consider?

    Featured image representing medico legal

    What's the Role of Expert Opinion in Medical Negligence?

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    View All

    Journal Club Today

    image representing junk food

    Study Reveals Junk Food Ads Drive Higher Calorie Intake in Children

    View All

    Health News Today

    Health Bulletin 12/ May/ 2025

    Health Bulletin 12/ May/ 2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok